In This Article:
TherapeuticsMD (NASDAQ:TXMD) Third Quarter 2024 Results
Key Financial Results
-
Net loss: US$567.0k (loss narrowed by 61% from 3Q 2023).
-
US$0.049 loss per share (improved from US$0.13 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
TherapeuticsMD shares are down 3.9% from a week ago.
Risk Analysis
You still need to take note of risks, for example - TherapeuticsMD has 3 warning signs we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.